Another Pancreatic-Cancer Setback - WSJ.com: "Bristol-Myers Squibb Co. and ImClone Systems Inc. said their cancer drug, Erbitux, failed to significantly prolong the lives of people with pancreatic cancer in a new study, marking yet another setback in the drug industry's efforts to find a better treatment for this deadly disease.
Erbitux is currently approved by regulators to treat colorectal cancer and head and neck cancer. Bristol-Myers and ImClone have been studying whether it is effective in other cancers."
Tuesday, April 10, 2007
Another Pancreatic Cancer Setback
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment